Advanced Search
LU Hao-yuan, BAI Xian-zhong. Expression of Cyclooxygenase-2 (COX-2)in Human Transitional Cell Carcinoma of Bladder and Its Relationship with HER-2 and p53[J]. Cancer Research on Prevention and Treatment, 2010, 37(05): 558-561. DOI: 10.3971/j.issn.1000-8578.2010.05.019
Citation: LU Hao-yuan, BAI Xian-zhong. Expression of Cyclooxygenase-2 (COX-2)in Human Transitional Cell Carcinoma of Bladder and Its Relationship with HER-2 and p53[J]. Cancer Research on Prevention and Treatment, 2010, 37(05): 558-561. DOI: 10.3971/j.issn.1000-8578.2010.05.019

Expression of Cyclooxygenase-2 (COX-2)in Human Transitional Cell Carcinoma of Bladder and Its Relationship with HER-2 and p53

More Information
  • Corresponding author:

    BAI Xian-zhong

  • Received Date: October 28, 2008
  • Revised Date: December 06, 2009
  • Objective To investigate the expression of COX-2, HER-2 and p53 in human transitional cell carcinoma of the bladder and their possible correlation. Methods SP immunohistochemistry staining was performed to evaluate the expression of COX-2, HER-2 and p53 in 56 cases of transitional cell carcinoma of the bladder and 10 cases of normal bladder mucosa. Results (1)The positive expression ratio of COX-2, HER-2 and p53 was 57.1%(32/56),51.8%(29/56)and 50%(28/56), respectively. The difference between carcinoma group and normal tissues group was statistically significant ( P <0.05). The expression of all above genes was related to clinic stage and the tumor grade ( P <0.05). (2) The expression of HER-2 and p53wassignificant correlation with the expression of COX-2 ( P <0.05). Conclusion The abnormal expression of COX-2, HER-2 and p53 might play a certain role in course of the occurrence, development of transitional cell carcinoma of the bladder. The over-expression ofCOX-2 in transitional cell carcinoma of the bladder was correlated with the expression of HER-2 and p53.
  • Related Articles

    [1]DUAN Xiaoyang, SHI Jian. Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 103-109. DOI: 10.3971/j.issn.1000-8578.2025.24.0856
    [2]WANG Jingyi, ZHONG Yuling, WU Lin. Immunotherapy for Advanced Non-small Cell Lung Cancer: Research Progress and Perspectives[J]. Cancer Research on Prevention and Treatment, 2024, 51(6): 409-418. DOI: 10.3971/j.issn.1000-8578.2024.24.0090
    [3]SUN Jiaqi, WANG Yudong. Treatment Strategy and Research Progress of Immune Microenvironment for Liver Metastasis of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(3): 203-209. DOI: 10.3971/j.issn.1000-8578.2024.23.0878
    [4]ZHENG Jianhong, TIAN Lin, ZHAO Peiyan, LI Hui, CHENG Ying. Research Progress on Efficacy-related Biomarkers of Immunotherapy in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(2): 127-133. DOI: 10.3971/j.issn.1000-8578.2024.23.0856
    [5]WANG Ganggang, WANG Xianhuo, ZHANG Huilai. Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1165-1173. DOI: 10.3971/j.issn.1000-8578.2023.23.0901
    [6]HAN Jing, CHEN Yarui, WANG Song, GUAN Quanlin. Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1139-1144. DOI: 10.3971/j.issn.1000-8578.2023.23.0447
    [7]WANG Tianming, ZHANG Liang, CHENG Ying. Progress of Research on Immune-related Pneumonia in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(8): 808-812. DOI: 10.3971/j.issn.1000-8578.2023.23.0075
    [8]SUN Yichu, LIANG Fei, XIA Youyou. Progress of Research on Radiotherapy Combined with Immunotherapy for Brain Metastases from Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 705-709. DOI: 10.3971/j.issn.1000-8578.2023.22.1322
    [9]MA Shishi, DAI Yuran, CHEN Xiaopin. Research Progress on Postoperative Adjuvant Therapy for Completely Resected Stage ⅠB Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 303-308. DOI: 10.3971/j.issn.1000-8578.2023.22.0933
    [10]JIANG Meilin, PENG Wenying, LI Jia, CHEN Bolin, WU Lin. Research Progress of Biomarkers for Immunotherapy on Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2018, 45(10): 805-810. DOI: 10.3971/j.issn.1000-8578.2018.17.1514

Catalog

    Article views (2292) PDF downloads (569) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return